J.S. Held Experts Recognized by ABF Journal as 2026 Legends & Leaders
Brian Gleason named an Icon and Michael Sutters recognized as a NextGen…
WhiteSwell Announces Primary Clinical Trial Results Simultaneously at Heart Failure 2026 Congress and in European Journal of Heart Failure related to the DELTA-HF Study in Acute Decompensated Heart Failure
GALWAY, Ireland, May 10, 2026 (GLOBE NEWSWIRE) -- WhiteSwell, a clinical-stage medtech…
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
March 28, 2026 15:00 ET | Source: Roivant Sciences The results of…
Novartis IgAN data in New England Journal of Medicine show Fabhalta slowed kidney function decline by 49.3%
“Persistent kidney inflammation is a hallmark of IgAN, and a key driver…
Wake Radiology Chief Operating Officer Parul Galloway Receives 2026 Women in Business Award by the Triangle Business Journal
RALEIGH, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Wake Radiology UNC Health…
ACTG Announces Publication of LATITUDE Findings in the New England Journal of Medicine
Study Confirms Long-Acting Treatment is Effective among People Living with HIV Who…
Rpharmy Honored With Family Business Award From Austin Business Journal
Austin-Based Healthcare Technology Provider Recognized for Community Impact, Life-Saving Solutions that Protect…
Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer
AGOURA HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc.…
Springer Nature honours Indian editors at Journal Development Symposium 2025. Brings Together Leading Editors and Publishing Experts to Shape the Future of Research Integrity and AI in Scholarly Communication
NEW DELHI, Oct. 31, 2025 /PRNewswire/ -- The day long Journal Development…
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
Long-term continuous OGSIVEO treatment for up to 4 years was associated with…
